Cerus Corporation (CERS)
NASDAQ: CERS · Real-Time Price · USD
1.850
-0.080 (-4.15%)
Mar 9, 2026, 1:46 PM EDT - Market open
Cerus Revenue
In the year 2025, Cerus had annual revenue of $206.13M with 14.35% growth. Cerus had revenue of $57.75M in the quarter ending December 31, 2025, with 13.66% growth.
Revenue (ttm)
$206.13M
Revenue Growth
+14.35%
P/S Ratio
1.74
Revenue / Employee
$327,195
Employees
630
Market Cap
355.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 206.13M | 25.86M | 14.35% |
| Dec 31, 2024 | 180.27M | 23.90M | 15.29% |
| Dec 31, 2023 | 156.37M | -5.68M | -3.51% |
| Dec 31, 2022 | 162.05M | 31.19M | 23.83% |
| Dec 31, 2021 | 130.86M | 38.94M | 42.36% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Varex Imaging | 854.40M |
| Viemed Healthcare | 270.28M |
| OrthoPediatrics | 236.35M |
| Pacific Biosciences of California | 160.01M |
| RxSight | 134.48M |
| Beta Bionics | 100.25M |
| NeuroPace | 99.99M |
| Standard BioTools | 85.33M |
CERS News
- 4 days ago - Cerus's Record 2025 Sets It Up For Another Leg Higher - Seeking Alpha
- 6 days ago - Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results - Business Wire
- 17 days ago - Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference - Business Wire
- 19 days ago - Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026 - Business Wire
- 6 weeks ago - DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT™ Blood System in Routine Clinical Practice - Business Wire
- 2 months ago - Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook - Business Wire
- 3 months ago - Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America - Business Wire